Etid klinik pou Melanom nan Minnesota
29 etid pou Melanom ap chèche patisipan nan sit nan Minnesota.
Vil nan Minnesota
- Rochester16 etid
- Minneapolis12 etid
- Saint Paul6 etid
- Duluth5 etid
- Brooklyn Park5 etid
- Plymouth5 etid
- Bloomington4 etid
Tèks ofisyèl etid la (Anglè)
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Riverwood Healthcare Center, Aitkin
- Mayo Clinic Health System in Albert Lea, Albert Lea
- Essentia Health - Baxter Clinic, Baxter
- ak 48 plis
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 40 a 75 · Tout sèks · Mizajou Oct 2, 2026 · NCT05334069A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
- Health Partners Frauenshuh Cancer Center, Saint Louis Park
- Health Partners Cancer Center at Regions Hospital, Saint Paul
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Oct 1, 2026 · NCT06172478BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
- Sanford Joe Lueken Cancer Center, Bemidji
- Essentia Health Saint Joseph's Medical Center, Brainerd
- Minnesota Oncology - Burnsville, Burnsville
- ak 18 plis
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT05136196A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)
- Minnesota Oncology Hematology, P.A, Fridley
- Allina Health Cancer Institute, Minneapolis
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT06246916Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.
- University of Minnesota, Minneapolis
Ap rekriteFaz 3
Laj 18 a 70 · Tout sèks · Mizajou Sep 24, 2026 · NCT05727904Pan-tumor MRD Study
- Mayo Clinic, Rochester
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Sep 24, 2026 · NCT06605404Comparing the Effectiveness of Less Invasive Procedures With the Current Standard of Care for the Treatment of Older Adults With Early-Stage Melanoma
- Sanford Joe Lueken Cancer Center, Bemidji
- Sanford Thief River Falls Medical Center, Thief River Falls
Ap rekriteFaz 3
Laj 75 ak plis · Tout sèks · Mizajou Sep 24, 2026 · NCT07068074Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
- Minnesota Oncology and Hematology PA, Minneapolis
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 18, 2026 · NCT05267626A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
- Local Institution - 0129, Rochester
- Local Institution - 0174, Rochester
- Local Institution - 0181, Rochester
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 16, 2026 · NCT07492680A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases
- Minnesota Oncology - Burnsville, Burnsville
- Cambridge Medical Center, Cambridge
- Mercy Hospital, Coon Rapids
- ak 21 plis
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 15, 2026 · NCT04511013ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
- Mayo Clinic (Rochester), Rochester
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Sep 14, 2026 · NCT05059444Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors
- Minnesota Oncology-Sarah Cannon Research Institute, Maple Grove
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 4, 2026 · NCT07287917A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors
- Mayo Clinic - Rochester, Rochester
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 2, 2026 · NCT04913285Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
- University of Minnesota/Masonic Cancer Center, Minneapolis
Ap rekriteFaz 1/2
12 Months – 30 Years · Tout sèks · Mizajou Aug 25, 2026 · NCT04851119Project: Every Child for Younger Patients With Cancer
- Children's Hospitals and Clinics of Minnesota - Minneapolis, Minneapolis
- University of Minnesota/Masonic Cancer Center, Minneapolis
- Mayo Clinic in Rochester, Rochester
Ap rekriteEtid obsèvasyon
Jiska laj 25 · Tout sèks · Mizajou Aug 25, 2026 · NCT02402244Digital Remote Monitoring of Immune Checkpoint Inhibitor Therapy Induced Toxicity Using the Vigilant App
- Mayo Clinic in Rochester, Rochester
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Aug 6, 2026 · NCT06675643A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
- M Health Fairview University of Minnesota Medical Center, Minneapolis
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Aug 5, 2026 · NCT06330064Integrated Cancer Repository for Cancer Research
- Riverwood Healthcare Center, Aitkin
- Essentia Health-St. Joseph's Medical Center, Brainerd
- Essentia Health - Duluth Clinic, Duluth
- ak 2 plis
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 19 a 110 · Tout sèks · Mizajou Jun 29, 2026 · NCT02012699Studying Quality of Life Inclusive of Mental Health and Cognitive Behavioral Therapy for Cancer Distress for the Improvement of Quality of Life in Stage III-IV Melanoma Patients
- Mayo Clinic in Rochester, Rochester
Ap rekrite
Laj 18 ak plis · Tout sèks · Mizajou Jun 22, 2026 · NCT07379138Evaluation of Anti-PD-1 Therapy by Monitoring T Cell Responses in Melanoma, Lung and Other Cancer Types
- Mayo Clinic in Rochester, Rochester
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Jun 18, 2026 · NCT06075524MC1R-targeted Alpha-particle Monotherapy and Combination Therapy Trial With Nivolumab in Adults With Advanced Melanoma
- Mayo Clinic Rochester, Rochester
Ap rekriteFaz 1/2
Laj 18 a 90 · Tout sèks · Mizajou Jun 10, 2026 · NCT05655312Neoadjuvant Darovasertib in Primary Uveal Melanoma
- Mayo Clinic - PPDS, Rochester
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou May 6, 2026 · NCT07015190A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
- Mayo Clinic Rochester, Rochester
Ap rekriteFaz 2/3
Tout laj · Tout sèks · Mizajou Apr 2, 2026 · NCT06581406Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
- Mayo Clinic Health System in Albert Lea, Albert Lea
- Essentia Health Saint Joseph's Medical Center, Brainerd
- Minnesota Oncology - Burnsville, Burnsville
- ak 31 plis
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Mar 17, 2026 · NCT06418204Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)
- University of Minnesota Medical Center, Minneapolis
- Mayo Clinic Minnesota, Rochester
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Feb 25, 2026 · NCT05549297Efficacy of Daromun Neoadjuvant Intratumoral Treatment in Clinical Stage IIIB/C/D Melanoma Patients
- Mayo Clinic, Rochester
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Dec 17, 2025 · NCT03567889A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
- Research Site 121, Saint Paul
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Nov 21, 2025 · NCT05914116SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Duluth
Ap rekriteEtid obsèvasyon
Tout laj · Tout sèks · Mizajou Oct 28, 2025 · NCT03452774A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)
- Mayo Clinic in Minnesota, Rochester
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Nov 25, 2024 · NCT05824975Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.